Vyome Holdings Inc. (HIND): Debt to Book Capitalization Ratio

Vyome Holdings Inc (HIND) is developing innovative immunological agents for the therapy of skin pathologies. The debt-to-equity ratio reflects the leverage dynamics, and this metric stands at 0.00. Business resilience is supported by patent protection and clinical trial results, while human capital is strengthened by the recruitment of experts in obesity and immunology.

HIND Vyome Therapeutics: Debt to Book Value in the range 08/16/2025 - 11/02/2026

Vyome Holdings Inc (HIND) competes in the high-risk immunological drug development sector. The debt-to-book value ratio quantifies the company's reliance on external financing to conduct clinical trials. This coefficient measures the proportion of borrowed funds within the equity structure. A decrease in this metric confirms financial autonomy, whereas an increase signals a rising debt burden. By analyzing the company's balance sheet financial leverage, an investor assesses the business's resilience to investment risks.

Competitors of Vyome Holdings Inc (HIND)

Debts to Book Capitalization ARGX (argenx SE)|Debts to Book Capitalization biontech.de BNTX|ABVX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ADMA (ADMA Biologics Inc)|Protagonist Therapeutics Inc (PTGX) - Debt to Book Capitalization Ratio|Debt to Book Value Immunovant Therapeutics|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com|Debt to Book Value ADPT (Adaptive Biotechnologies Corporation)|CLDX (Celldex Therapeutics Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization AUPH (Aurinia Pharma)|Debts to Net Assets BioCryst Corp (BCRX)|VERA - Debt to Book Capitalization Ratio|dianthustx.com (DNTH) - Debt to Book Value|Pharvaris (PHVS) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|Debt to Book Value TRML|Debts to Book Capitalization Precigen Corp|Debt to Book Capitalization Ratio Pharming Group N.V. (PHAR)|nektar.com - Debt to Book Value Ratio|Debts to Book Capitalization UPB (Upstream Bio)|Zenas Bio (ZBIO) - Debts to Book Value|IMNM: Debt to Book Value|GOSS: Debt to Book Capitalization Ratio|KALV (KalVista Pharmaceuticals) - Debt to Book Value|Debts to Book Value septerna.com (SEPN)|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.|Debts to Book Value Savara Inc SVRA|Debt to Book Capitalization Ratio Rigel Pharmaceuticals Inc (RIGL)|Debt to Book Value AnaptysBio Inc. ANAB|Debts to Book Capitalization ATXS (Astria Therapeutics)|engene.com (ENGN) - Debts to Book Value|RAPT: Debt to Book Value|Debt to Net Assets Ratio JBIO (Aerovate Therapeutics Inc)|ACRS: Debts to Book Capitalization|Kyverna Therapeutics, Inc - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Tiziana Life Sciences|Debts to Book Value cabalettabio.com CABA|Debt to Book Capitalization Ratio Ventyx Biosciences, Inc. (VTYX)|Debt to Book Capitalization Ratio THTX (Theratechnologies, Inc.)|Debts to Book Capitalization AVTX (Avalo Therapeutics Inc.)|ELDN: Debt to Book Value Ratio|Agenus - Debts to Book Capitalization|Debts to Net Assets climbbio.com CLYM|Zura Bio Limited (ZURA) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio ATYR|ADAG (Adagene Inc) - Debts to Book Capitalization|IMA - Debt to Net Assets|Debt to Book Capitalization Ratio Shattuck Labs, Inc. (STTK)|Debts to Net Assets equilliumbio.com|Connect Biopharma Holdings Limited - Debt to Book Value|Debt to Net Assets Ratio IMUX|Atara Biotherapeutics Inc - Debts to Book Capitalization|Debts to Net Assets InflaRx N.V. IFRX|X4 Pharmaceuticals (XFOR) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio ACET|CELU (Celularity Inc) - Debts to Book Capitalization|Debt to Book Value INmune Bio Inc (INMB)|Debts to Book Capitalization BRNS|KZR (Kezar Life Sciences Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization SABS (SAB Biotherapeutics)|Debts to Net Assets akaritx.com (AKTX)|ENLV - Debt to Book Capitalization Ratio|QTTB (Q32 Bio Inc.) - Debt to Book Value Ratio|GOVX: Debts to Book Capitalization|Debt to Book Value Ratio EDSA|Debt to Book Capitalization Ratio iBio, Inc.|Carisma Tx - Debts to Book Capitalization Ratio|Debts to Book Capitalization XTLB|BOLT (boltbio.com) - Debt to Net Assets Ratio|Debts to Book Capitalization HCWB (HCW Biologics)|Debts to Book Capitalization Aptevo Therapeutics, Inc. APVO|AIM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ADTX (Aditxt)|GRI Bio (GRI) - Debt to Book Capitalization Ratio|Debt to Book Value XORTX Therapeutics Inc|REVB (Revelation Bio) - Debts to Book Capitalization|Debts to Book Capitalization Indaptus Corp|Debt to Book Value SCNI (Scinai Immunotherapeutics)|CALI (calcimedica.com) - Debt to Net Assets Ratio|Debts to Book Capitalization AFMD (Affimed N.V.)|Debts to Net Assets Allakos Inc (ALLK)|HOOK - Debt to Book Capitalization Ratio|IGM Biosciences, Inc. (IGMS) - Debt to Book Value|iTeos Therapeutics (ITOS) - Debt to Book Capitalization Ratio|Debt to Book Value oceanbiomedical.com|Debt to Book Value TCBP|Debts to Book Capitalization Third Harmonic Bio Inc.